Head-to-head evidence
Arlocabtagene autoleucel vs JNJ-87562761
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Multiple Myeloma
Shared mechanism: GPRC5D · full Multiple Myeloma pipeline
Arlocabtagene autoleucel
Developed by Juno Therapeutics, Inc. and partners
NCT04674813 · Phase 1 · completed
Everyone enrolled knowingly received the therapy, with no random assignment and no comparison group, so response and safety data cannot be separated from how this particular group of patients would have fared anyway. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
Next expected readout: December 2027 · NCT06615479 (registry estimate)
JNJ-87562761
Developed by Johnson & Johnson
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: November 2027 · NCT06604715 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Arlocabtagene autoleucel's landscape · JNJ-87562761's landscape